$8.740
-0.419 (-4.79%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de BBOT por análisis de gráficos similares
Alphio's BBOT stock price prediction model matches the current BridgeBio Oncology Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $8.68 (-0.74%). The 1-week path is $8.83 (+1.08%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de BridgeBio Oncology Therapeutics Inc?
Helix Acquisition Corp II (BBOT) is not a good buy right now due to its current price of $8.74, which is significantly below analyst price targets ranging from $22 to $29. The stock has a low RSI of 33.785, indicating it is oversold, but the negative catalysts such as a consistent decline in net income and a projected EPS of -0.71 suggest ongoing financial struggles. The main risk is the high forward P/E ratio of 0, indicating uncertainty in future earnings.
BBOT cerró en $8.74 el Friday, tras bajar -4.79%
BridgeBio Oncology Therapeutics Inc (BBOT) last closed at $8.74, losing -4.79%. These facts feed the 1-day and 1-week BBOT price prediction above.
Factores de la previsión
Los factores de la previsión de BridgeBio Oncology Therapeutics Inc (BBOT) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de BBOT, ordenadas por similitud.
Análisis de estacionalidad de BBOT
Historically the probability of a positive August return for BBOT is 11.43%. October offers the highest probability of a positive month at 100.00%, while February is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.